SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. ($UUUU) is trending amid speculation around upcoming earnings and potential government contracts related to uranium and rare earth elements. Community discussions highlight the stock's volatility, with some traders pointing to unusual options activity and anticipating a significant price movement. Others suggest that any pullback represents a buying opportunity, citing the company's strategic importance in securing domestic supply chains.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is trending as rumors of potential acquisition swirl, with the community buzzing about a potential buyout after reports of a failed financing attempt from a smaller company.  Enthusiasm is building for the upcoming earnings report and the potential for a positive outcome, while some investors express skepticism toward management. Bullish sentiment is further fueled by high short interest, leading to speculation about a possible short squeeze.

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

NewcelX Ltd.

NCEL is trending as investors grapple with the implications of its recent merger and reverse stock split, with some expressing confusion and concern over trading discrepancies and stock valuations. Community discussions revolve around the potential for a short squeeze and the company's future prospects post-merger. The merger with Kadimastem is seen by some as a positive catalyst, while others remain skeptical about the combined entity's valuation and potential.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors discuss its high valuation and potential ahead of earnings, with some pointing to strong AI growth and government contracts as reasons for optimism. The community is debating whether the stock can maintain its momentum and if it will beat expectations. Discussions include potential stock splits and comparisons to other high-growth tech companies.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals ($BCRX) is trending as investors anticipate upcoming earnings and key updates on its pipeline, including BCX17725 for Netherton syndrome. Community discussions focus on the potential for a positive conference call with improved guidance, overshadowing concerns about debt and valuation. Optimism surrounds the integration of Astria's assets and potential label expansion for Orladeyo, as analysts project earnings growth.

Space and Time is the Microsoft-backed blockchain for ZK-proven data. Powered by Proof of SQL, a sub-second ZK coprocessor, Space and Time allows smart contracts, AI agents, and onchain applications to query onchain and offchain data at scale and verify the results with cryptographic proofs. The foundation of Space and Time is a decentralized layer 1 blockchain where validators verify every piece of data that gets inserted into the network, updating and signing cryptographic commitments on the data before recording them onchain. Developers can query this data via Proof of SQL and receive back a trustless, tamperproof result onchain. Space and Time allows smart contracts to query over the full history of major blockchains and offchain sources in a verifiable way, enabling a new generation of sophisticated, data-driven onchain apps.  The SXT token is deployed as an ERC-20 token on Ethereum and functions as the network's native utility token. SXT is used for staking, data processing payments, access control, and incentives for data contributors.

Space and Time

Space and Time ($SXT) is trending amid community excitement surrounding its technology and partnerships, particularly with Microsoft and Chainlink. Discussions center on its potential for growth in the AI and decentralized data space, with some highlighting recent integrations and others anticipating a breakout. The community is closely watching for further developments that could drive broader adoption and price appreciation.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

GILD is trending due to recent earnings and analyst upgrades, though the stock's reaction is mixed, with some questioning if investor expectations weren't fully met. Community discussions revolve around the company's HIV and oncology pipeline, potential acquisitions (such as RCUS or XLO), and the impact of regulatory decisions. Several actionable alerts and technical analyses are being shared, with call options being a popular strategy.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is trending amid speculation around winter weather and potential supply constraints, with some traders anticipating a significant rally. Community discussions revolve around technical indicators, potential breakout levels, and the impact of data center energy consumption on natural gas demand. Despite strong storage levels, expectations of increased demand and potential disruptions are fueling bullish sentiment.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X Shares

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is trending due to LiquidTheta's LEAPS options alerts, sparking community interest in potential ROI. Additionally, news of China and Canada expanding trade and energy ties could provide tailwinds. However, concerns about consumer recession, layoffs, and banking stress are also circulating, adding complexity to the discussion around JNUG and junior gold miners.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton is trending as the community discusses its potential for a turnaround, fueled by recent analyst upgrades and speculation around new AI-integrated products. Community members are debating whether the stock is poised for a Carvana-like surge, while others caution about the impact of the broader economic environment and short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Merus N.V. (NasdaqGM: MRUS) to Genmab A/S...

Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders

Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders Halper Sadeh LLC Investigates FSFG, MTSR, VRNT, MRUS on Behalf of Shareholders PR Newswire NEW YORK, Oct. 21, 2025 NEW...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate Merger - FSFG, MTSR...

GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal

Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.

Merus&nbsp;NV’s stock climbed to a record high on Monday after Genmab said it would acquire the company in an $8 billion all-cash transaction, despite a broad wave of analyst downgrades.<a href="https://stocktwits.com/symbol/MRUS">Shares of Merus</a> jumped 36% to close at $93.70 on Monday, before edging up 0.1%, in after-hours trading.Needham analyst Ami Fadia downgraded Merus to ‘Hold’ from ‘Buy’ without a price target after the company entered into the agreement. Citi downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $97 from $101, saying the possibility of a competing bid is very low.Wells Fargo analyst Eva Fortea Verdejo lowered her rating to ‘Equal Weight’ from ‘Overweight’ and raised the price target to $97 from $95. Canaccord downgraded Merus to ‘Hold’ from ‘Buy’ with a price target of $97, while William Blair cut its rating to ‘Market Perform’ from ‘Outperform’.Truist moved Merus to ‘Hold’ from ‘Buy’ and raised the price target to $97 from $88, saying the deal terms are “favorable, all things considered.”LifeSci Capital analyst Charles Zhu downgraded Merus to ‘Market Perform’ from ‘Outperform’ with a price target of $97. Guggenheim analyst Michael Schmidt downgraded the stock to ‘Neutral’ from ‘Buy’ and cut the target to $97 from $109.H.C. Wainwright downgraded Merus to ‘Neutral’ from ‘Buy’ and reduced its price target to $97 from $135, saying Merus’ full value is priced into the deal.The transaction, unanimously approved by both companies’ boards, gives Genmab full ownership of petosemtamab, Merus’ late-stage antibody therapy for head and neck cancer, which has received two Breakthrough Therapy Designations from the U.S. Food and Drug Administration.On Stocktwits, retail sentiment for Merus was ‘extremely bullish’ amid a 3,800% surge in 24-hour message volume.Some users congratulated Merus shareholders on the buyout, saying the acquisition marked a rewarding moment for long-term investors who held through difficult periods.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/630422083</stembedurl><stembedurl>https://stocktwits.com/Following_the_trend/message/630325826</stembedurl>Another user noted that the deal underscored the potential for other biotech firms to be acquired at higher valuations, citing that Merus was acquired by Genmab for $8 billion, despite its focus on the relatively smaller head and neck cancer market.<stembedurl>https://stocktwits.com/Power2k/message/630394868</stembedurl><a href="https://stocktwits.com/symbol/MRUS">Merus’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Merus logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal

The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.

Equity

Retail chatter around Merus spiked late on Sunday after a report said Denmark’s Genmab is reportedly in advanced talks to acquire the Dutch biotech, which is developing a potential treatment for head and neck cancer.<a href="https://stocktwits.com/symbol/MRUS">Merus’ U.S.-listed stock</a> closed at $68.89 on Friday, up 1.2%, and surged over 19% to $82.03 in overnight trading.Merus has reportedly received multiple takeover offers from large pharmaceutical companies in recent weeks and could announce a deal within days, although there is no certainty that the talks will result in a transaction, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-28/genmab-is-said-in-talks-to-buy-cancer-drugmaker-merus?srnd=homepage-americas&amp;sref=8QBk7toa">reported</a>, citing people familiar with the matter.If finalized, the deal would be Genmab’s largest acquisition to date, Bloomberg reported. Genmab has a market capitalization of about 118 billion kroner ($18.5 billion), while Merus is valued at around $5.2 billion on the Nasdaq.Merus’ shares have risen sharply since May, when the company said its experimental drug petosemtamab was more effective than the current standard of care in shrinking tumors in head-and-neck cancer patients when combined with Keytruda. Bloomberg Intelligence has forecast that the drug could become a blockbuster therapy and exceed $1 billion in sales by 2030.Merus is also testing petosemtamab in advanced colon cancer, a larger and more lucrative potential market. Its smaller rival, Bicara Therapeutics, is developing a treatment for the same condition but remains further behind in development.On Stocktwits, retail sentiment for Merus was ‘bullish’ amid ‘high’ message volume, placing the stock among the top ten trending equities on the platform. Meanwhile, Genmab drew ‘extremely bearish’ sentiment amid ‘high’ message volume.One user congratulated the company on the reported development, while another user asked about the potential buyout price, reflecting curiosity about the rumored deal’s details.<stembedurl>https://stocktwits.com/CrispDry/message/630278149</stembedurl><stembedurl>https://stocktwits.com/Fugazi_/message/630280727</stembedurl>Merus’ U.S.-listed stock has risen 63.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race

Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

Merus (MRUS) delivered earnings and revenue surprises of -90.60% and -15.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of +39.81% and +7.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.Oncology company Merus on Thursday <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.merus.nl/news-releases/news-release-details/merus-petosemtamab-pembrolizumab-interim-data-demonstrates">said</a> that the combination of bispecific antibody Petosemtamab with Pembrolizumab demonstrated robust efficacy and durability in its ongoing phase 2 trial as of Feb. 27.Merus CEO Bill Lundberg said the data from the trial demonstrates that Petosemtamab in combination with Pembrolizumab can become “a new standard of care" in head and neck cancer and is “significantly better” than treatment with just Pembrolizumab.The company said that as of Feb. 27, 45 patients had been treated in the phase 2 trial, and the combination was generally well tolerated.The CEO also expressed optimism about sharing data from one or both of its late-stage combination trials in 2026.BofA on Friday hiked the price target on Merus to $92 from $70 while keeping a ‘Buy’ rating on the shares. The firm noted that the recently announced data set the combination as "the best-in-class treatment option for this patient population."The analyst’s new price target implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.BMO Capital also hiked the price target on Merus to $110 from $96 on Friday while keeping an ‘Outperform’ rating on the shares. BMO said it sees a 90% probability of the combination's approval for treating head and neck cancer.On Stocktwits, retail sentiment around Merus jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_10_48_55_AM_png_3d759215e6.webp" alt="MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/MRUS">MRUS stock</a> is up by about 30% this year and 25% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jp-morgan-bank-of-america-citigroup-wells-fargo-reportedly-explore-joint-stablecoin/ch0QZ5vRbqs">JPMorgan, Bank of America, Citigroup, Wells Fargo Reportedly Explore Joint Stablecoin</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled

BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

MRUS
Merus N.V

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRUS News

MRUSMerus N.V